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Elevated MTSS1 expression associated with
metastasis and poor prognosis of residual
hepatitis B-related hepatocellular
carcinoma
Xiu-Yan Huang1*†, Zi-Li Huang2†, Bin Xu3†, Zi Chen4, Thomas Joseph Re5, Qi Zheng1, Zhao-You Tang6
and Xin-Yu Huang1*
Abstract
Background: Hepatectomy generally offers the best chance of long-term survival for patients with hepatocellular
carcinoma (HCC). Many studies have shown that hepatectomy accelerates tumor metastasis, but the mechanism
remains unclear.
Methods: An orthotopic nude mice model with palliative HCC hepatectomy was performed in this study.
Metastasis-related genes in tumor following resection were screened; HCC invasion, metastasis, and some molecular
alterations were examined in vivo and in vitro. Clinical significance of key gene mRNA expression was also analyzed.
Results: Metastasis suppressor 1 (MTSS1) located in the central position of gene function net of residual HCC. MTSS1
was up-regulated in residual tumor after palliative resection. In hepatitis B-related HCC patients undergone palliative
hepatectomy, those with higher MTSS1 mRNA expression accompanied by activation of matrix metalloproteinase 2
(MMP2) in residual HCC, had earlier residual HCC detection after hepatectomy and poorer survival when compared to
those with lower MTSS1. In different cell lines, the levels of MTSS1 mRNA increased in parallel with metastatic potential.
MTSS1 down regulation via siRNA decreased MMP2 activity, reduced invasive potentials of HCC by 28.9 % in vitro, and
averted the deteriorated lung metastatic extent in vivo.
Conclusions: The poor prognosis of hepatitis B-related HCC patients following palliative hepatectomy associates with
elevated MTSS1 mRNA expression; therefore, MTSS1 may provide a new research field for HCC diagnosis and treatment.
Keywords: Metastasis suppressor 1, Hepatocellular carcinoma, Invasion, Metastasis
Background
Liver cancer in men is the fifth most frequently diag-
nosed cancer worldwide but the second most frequent
cause of cancer-related deaths; in women, it is the sixth
most commonly diagnosed cancer and the sixth leading
cause of cancer-related deaths [1]. Among primary liver
cancers, hepatocellular carcinoma (HCC) represents the
major histological subtype, accounting for 70 to 85 % of
the total liver cancer burden worldwide [2]. Hepatic
resection is a standard treatment for patients with HCC.
However, even in patients with HCC undergoing cura-
tive resection, it is only potentially curative due to the
existence of tumor cells or clinically undetectable re-
sidual intrahepatic lesions [3]. Our clinical data showed
that the proportion of cases with palliative hepatectomy
was 34.0 % from 1958 to 2008 (2754/8107, unpublished
data). Our follow-up research suggests that HCC pa-
tients treated with palliative hepatectomy suffered from
dramatically worsened metastases, suggesting that pal-
liative hepatectomy enhances the metastatic potential
of residual HCC. Although surgery is associated with
tumor suppression and prolonged survival in a few
cases [4], increasing number of reports indicate that
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hepatic resection exacerbates tumor growth and trig-
gers tumor metastasis [5–7]. We found that palliative
resection enhances the metastatic potential of residual
HCC [5]. The present study sought to explore the
underlying molecular mechanism of this metastasis-
enhancing effect.
The incidence, development, invasion, and metastasis
of HCC are regulated by the activation, inactivation, or
dysregulation of several genes. This study employed an
orthotopic human HCC model with high metastatic
potential in nude mice. This model was developed at
Liver Cancer Institute, Fudan University [5, 8]. Using
Human Tumor Metastasis Microarray, we screened the
metastasis-related genes in tumor tissues following pal-
liative resection, and found that up-regulated metasta-
sis suppressor 1 (MTSS1) was located in the central
position of gene function net of residual HCC in liver.
MTSS1 is also known as “missing in metastasis”
(MIM) gene. Among the multiple MIM gene products
including MIM-A, MIM-B and MIM-C, MIM-B is the
longest and most abundant protein in the cell, which is
representative of MIM protein [9]. MTSS1 has been pro-
posed as a potential metastasis suppressor gene in some
studies of HCC [10, 11]. However, other studies have
shown that MTSS1 is highly expressed in various tumors
[12, 13], including HCC [14]. MTSS1 may have an im-
portant role in tumor metastasis [12, 15, 16]. MTSS1/
MIM over-expression is associated with enhanced cell
migration, resulting in tumorigenesis, invasion and me-
tastasis [17–19], and predicts poor prognosis in colorec-
tal cancer [20], cervical carcinoma [21], and lung cancer
[22]. Recently, Mertz et al. reported that MTSS1 pro-
motes the metastasis of melanocytes, and high MTSS1
expression defines a subgroup of primary melanomas
with unfavorable prognosis [23]. It remains unclear
whether or not MTSS1 plays a role in metastasis of
residual HCC following palliative resection. HCC me-
tastasis involves basement membrane invasion follow-
ing matrix metalloproteinase (MMP) activation [24].
Previously, we found that palliative resection activates
MMP2 in nude mouse models with HCC [5]. In this
study, we first screened the metastasis-related genes in
residual HCC tissues, and found that MTSS1 was lo-
cated in the central position of the tumor gene net-
work. We investigated the MTSS1 mRNA expression in
residual tumor and analyzed its association with prog-
nosis in patients with hepatitis B-related HCC after
palliative resection. Subsequently, using in vitro and in
vivo studies, we found that MTSS1 enhanced the inva-
sive and metastatic potential of HCC cells via MMP2
activation. To our knowledge, the current study pro-
vides the first evidence that elevated MTSS1 mRNA
expression exacerbates lung metastasis after palliative
resection in an HCC model, with poor prognosis of
hepatitis B-related patients with HCC treated with pal-
liative hepatectomy.
Methods
Patients, specimens and follow-up
The inclusion criteria for patients in this study were (a)
patients with hepatitis B from 2000 to 2010; (b) patho-
logically proven HCC based on WHO criteria; (c) no
anticancer treatment prior to first hepatectomy; (d) sur-
gical resection twice in 6 months; (e) availability of
frozen biopsy and/or resected tissues expressing HCC
and residual HCC; and (f ) availability of follow-up data.
This study was approved by the Research Ethics Com-
mittee of the Shanghai Jiaotong University Affiliated
Sixth People’s Hospital, and informed consent was
obtained from each patient. HCC patients with hepa-
tectomy were followed up every 2 months during the
first postoperative year and at least every 3 to 4 months
subsequently, until December 2014 by monitoring
serum α-fetoprotein (AFP) levels, abdominal ultrason-
ography, chest X-ray or computed tomography every 1
to 6 months depending on the patient’s condition.
Residual HCC was suspected 2 months after first hepa-
tectomy (HCC-P I group, n = 37) in all patients and was
confirmed by fine needle autopsy and/or secondary sur-
gery (HCC-P II group, n = 37) in 6 months after the
first resection. Forty patients with radical hepatectomy
(complete resection of tumor with the cut surface free
of cancer histologically) and without recurrence at least
12 months after surgery (HCC-R group), and 20 liver
tissues from patients with hepatic hemangioma com-
bined with hepatitis B who underwent liver resection
were also collected (Liver-T group). All specimens were
collected in the operating room immediately (≤15 min)
after tissue removal and were snap frozen in liquid ni-
trogen and stored at −80 °C. General data, metastatic
characteristics, pathologic characteristics and survival
were compared among the groups.
Animals, tumor models and cell lines
Five-week-old male athymic BALB/c nu/nu mice weighing
18–20 g each were obtained from the Shanghai Institute
of Materia Medica, Chinese Academy of Science. All mice
used in these investigations were handled in accordance
with the Guide for the Care and Use of Laboratory
Animals (National Research Council, 1996), and were
approved by the Institutional Animal Care and Use com-
mittee of the Shanghai Jiaotong University Affiliated Sixth
People’s Hospital. A stepwise metastatic human HCC
model system was established in Liver Cancer Institute of
Fudan University, which included a metastatic HCC model
in nude mice LCI-D20 [8], a HCC cell line MHCC97 with
high metastatic potential that originated from LCI-D20
tumor, a high metastatic subclone (MHCC97H with a
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pulmonary metastatic rate up to 100 % using orthotopic in-
oculation) and a lower metastatic subclone (MHCC97L
with a lung metastatic rate up to 40 % using orthotopic
inoculation) established through in vivo selection of
MHCC97 [25]. The noninvasive human liver cell line of
L02 (normal), human HCC cell lines of Hep3B with very
low invasiveness [26], and highly invasive MHCC97H
[25], SMCC7721, MHCC97L, HCCLM3 and HCCLM6
were prepared in this study.
Mice grouping and treatment
Human HCC tumor models produced by MHCC97H
were established in nude mice by orthotopic inoculation
[8]. Briefly, under anesthesia, the left lobe of the liver
was exposed, and part of the liver surface was mechanic-
ally injured with scissors. A piece of MHCC97H tumor
tissue (size 2 × 2 × 2 mm) was fixed within the liver tis-
sue. Thirty-six nude mice were used in this study.
In the trial experiment, we treated MHCC97H cells
with mouse plasma extracted at different time intervals
after palliative hepatectomy in nude mice bearing HCC.
We found that these cells showed two trans-membrane
peaks: one occurring at the 12th hour post-hepatectomy
and the other occurring on day 14 post-hepatectomy. In
our mouse model, by the day 14 post-hepatectomy, lung
metastasis occurred in a majority of the cases. Therefore,
we selected the day 14 as a cut-off point to study re-
sidual HCC and related lung metastasis, subsequently.
Eighteen nude mice bearing HCC xenografts were ran-
domized into three groups 14 daysays after orthotopic
implantation: palliative resection group (mice undergo-
ing partial HCC resection with preservation of 2 mm of
tumor pedicles), sham operation group (mice with ex-
posed liver but without resection), and blank control
group (mice without further surgical intervention). All
mice were sacrificed by cervical dislocation 14 days after
palliative resection based on pre-experimental results
(Additional file 1: Figure. S1A and B). The HCC tissues
excised first were designated as tumor tissues T1; tissues
excised next from sham operation group were named
T2; tissues from blank control group were named tumor
tissues T3; and those derived from palliative resection
group were denoted T4 that represented residual HCC.
Five randomly selected tumor specimens from each
group were used for the screening of genes related to
metastasis by microarray techniques. Another 18 nude
mice treated with palliative resection were randomly
injected at multiple points with 100 μL borate-buffered
saline (BBS, BBS group), 2 × 107 U Lenti-GFP (Lenti-
GFP group) or Lenti-MTSS1 (Lenti-MTSS1 group),
respectively, under ultrasound guidance, and the proced-
ure was repeated 3 h later. All mice were sacrificed by
cervical dislocation 14 d post-resection for the evalu-
ation of early metastasis.
Parameters, sample preparations and grading of lung
metastasis
Mice were sacrificed for gene profiling of pulmonary
metastatic nodules. Lung tissues, tumor tissues,
mRNA and protein extracts were harvested for further
studies. Serial sections of lung tissue measuring 5 μm
in thickness were obtained, and all metastases were
verified histologically. The degree of lung metastasis
was graded by the maximum number of tumor cells
counted in the solitary pulmonary metastatic nodules
(grades): grade I, < 20; grade II, 20–50; grade III, 50–
100; and grade IV, > 100 [27].
Tumor metastasis-related gene profiling
In recent years, more and more researches employed Hu-
man Tumor Metastasis Microarray to dissect the gene
function and form gene regulatory network in various of
cancers [28–30]. Thus, the Human Tumor Metastasis
Microarray is useful in searching for new therapeutic tar-
geted genes and helpful in dissect mechanism of the gene
in several of cancers [31, 32]. The OHS-028 OligoGEAr-
ray Human Tumor Metastasis Microarray (Super Array,
Bethesda, MD) was used to characterize the metastasis-
related gene expression profiles of HCC tissues in this
study. GEArray Expression Analysis Suitesoft ware was
used for gene analysis. The methods of Support Vector
Machine (SVM), gene significance analysis and gene cor-
relation degree analysis were adopted to detect the poten-
tial markers involved in HCC metastasis. To further
explore the relationship between gene function and gene
function, we built the GO-network (gene function net). In
the GO-network, the degree represented the relationship
between GO terms. The key GO terms in the network
were signal transduction, multicellular organismal de-
velopment, ion transport, and signal transduction in
the GO terms. Among them, multicellular organismal
development, GO terms had the highest degree in the
network. Then, a gene function net was constructed
based on specific gene clustering analysis and multi-
dimensional scale [33, 34].
This study describes the advantages of using Support
Vector Machines algorithm for the classification of
gene expression data. Using the RVM model, we found
the different genes including the d genes from micro-
array data. Our conclusions are as follows. The char-
acteristic of samples, which amount to n was allocated
the different gene set, and we obtain a matrix (X)n × d
from the samples. The liver cancers samples, which
are high or low, constituted the dataset of {xi, yi}(i =
1, 2,⋯, n), where the xi represents the d dimension
vector, and yi ∈ {high = 1, low = − 1} is the class label.
We obtained an optimal hyperplane derived from the
SVM algorithm. The optimal hyperplane that is high
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and low is as follows: Minimizing 12 ωk k2 and Subject
to yi × 〈xi, ω〉 + b ≥ 1. From the quadratic form, we se-
lected the Support Vectors which carried weights, and
decision functions as follows: f xð Þ
∧




αiyi xi;Xh i þ b0
 !
. We transformed the non-
linear Microarray data into linear format using the gauss
and ploy kernel functions. Gauss kernel function was as fol-
lows: k xi; ; xj
  ¼ exp − xi−xjk k2σ2
 
¼ Φ xið Þ;Φ xj
  
. The
ploy kernel function was as follows: k(xi, xj) = (〈xi
T, xj〉 +
1)d = 〈Φ(xi),Φ(xj)〉, where 〈Φ(xi),Φ(xj)〉 is a scalar product.
Because the {x1, x2,⋯, xn} represents nonlinear space,
we transformed the vector xi into high-dimensional
feature space using the kernel function. The predic-
tion function is as follows: f xð Þ
∧




αiyi Φ xið Þ;Φ Xð Þh i þ b0
 !
. We demonstrated
that the gauss kernel function was effective with a
predictive accuracy close to 90 %.
The expression datasets presented in this publication
have been deposited in NCBIs Gene Expression Omni-
bus (http://www.ncbi.nlm.nih.gov/geo/) and are access-
ible through GEO Series accession number GSE75965.
Hematoxylin and eosin (H&E) stains
Paraffin blocks of 10 % buffered formalin-fixed samples
of tumor and lung tissues were prepared, and 5–μm-
thick serial sections were obtained. Pulmonary meta-
static nodules were verified via Hematoxylin and Eosin
(H&E) stains.
Real-time fluorescent quantitative polymerase chain
reaction (Real-time PCR)
The primers used for real-time polymerase chain reac-
tion (PCR) were designed using Primer Premier 5.0
(Premier Biosoft International, Palo Alto, CA): human
MTSS1 forward, 5′-tagctggaaggactgggcta-3′, and reverse,
5′-agtcatgctccgtggtctct-3′. GAPDH forward and reverse
primers were 5′-ggtgaaggtcggagtcaacg-3′ and 5′-accatg-
tagttgaggtcaatgaagg-3′, respectively. PCR was performed
in the Rotor-Gene 3000 PCR system (Corbett Research,
Sydney, Australia). Conditions for PCR were 37 °C for
2 min, 94 °C for 3 min, 40 cycles for GAPDH of 94 °C for
5 s, 60 °C for 40 s, followed by 37 °C for 5 s, and 95 °C for
30 s, 95 °C for 30 s, 40 cycles for MTSS1 of 95 °C for 15 s,
60 °C for 15 s, 72 °C for 30 s. Finally, baseline and thresh-
old values of these genes were set using the Rotor-Gene
6.0 (Corbett Research) for analysis.
Western blot
Proteins were separated by 10 % sodium dodecyl sulfate
-polyacrylamide gel electrophoresis and transferred
onto polyvinylidene difluoride membranes (Millipore,
Bedford, MA). The membrane was blocked with 5 %
non-fat dried milk in TBST (20 mM Tris–HCl,
150 mM NaCl, and 0.1 % Tween 20, pH 7.5) for 2 h
and incubated overnight with antibodies against MTSS1
(Abnova, Caltag-Medsystems Ltd., Buckingham, UK) at
4 °C. After washing with TBST buffer, membranes were
incubated with horseradish peroxidase-conjugated anti-
mouse IgG secondary antibodies for 1 h at room
temperature and detected by enhanced chemilumines-
cence detection system (Amersham-Pharmacia Biotech,
Braunschweig, Germany). GAPDH was used as an internal
control (Santa-Cruz Biotechnologies, California, USA).
siRNA design and lentivirus construction
The small interfering RNA (siRNA) sequences targeting
MTSS1 were designed according to a modified Tuschel
















The target 2 sequences were selected for further study.
The siDNA sequences matching the designed siRNA
were then amplified with PCR and inserted into a mouse
U6 promoter-driven lentivirus plasmid (purchased from
Genechem Co., Shanghai, China), in which a luciferase
expressing construct was then incorporated, forming the
pGCL-MTSS1-GFP plasmid. In brief, the infectious titer
was determined by fluorescence-activated cell sorting
analysis of GFP-positive in 293 T cells. The virus titers
were in the range of 107 transducing units/mL medium.
Stable lentiviral transfection of HCC cells
HCC cells were plated in 24-well plates. Subconfluent
cells were infected with 3 mL/well three times (about
3 h per infection). The cells were divided into three
groups: the knockdown cells transfected with MTSS1
siRNA lentivirus (KD group), the negative control cells
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transfected with empty lentivirus (NC group) and the
blank control cells not transfected (CON group).
MTSS1 overexpression
The full sequence of MTSS1 was amplified by the stand-
ard PCR procedure. The primer sequences for cloning
include sense primer: ATGGAGGCTGTGATTGAG; and
antisense primer: CTAAGAAAAGCGAGGGG. We trans-
fected the pCMV6-empty and pCMV6-MTSS1 into
Hep3B cancer cells and RNA and protein were extracted.
MTSS1 overexpression was confirmed, and invasive po-
tential assessed.
In vitro invasion assay
The MHCC97H cells (5 × 104 cells/well) treated with
MTSS1 siRNA lentivirus, empty lentivirus or with con-
trol (no treatment) were added to the upper chamber
(100 μL DMEM), and 600 μL conditioned medium was
added to the lower chamber. After 24 h of incubation,
the invaded cells were fixed with methanol and stained
with crystal violet solution. The results were expressed
as the number of penetrated cells under a microscope at
200× magnification in five random fields and presented
as the means ± SD of three assays.
Gelatin zymography assay
Zymography for MMP2 activity was conducted via so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) [35], with modification. The MHCC97H
cells (5 × 104 cells/well) treated with or without MTSS1
siRNA lentivirus were serum-starved for 24 h before cell
supernatant collection. The molecular weights of these
bands indicating MMP2 activity were determined by
molecular weight standards (Bio-Rad Laboratories,
Hercules, CA). The assays were conducted in triplicate.
MMP2 activity assay
Human MMP2 activity was quantified with an enzyme-
linked immunosorbent assay (ELISA) System (Amersham
Pharmacia Biotech, Piscataway, NJ) according to the
manufacturer’s instructions. The plate was read at
450 nm in a SPECTRAmax 250 Microplate Spectro-
photometer (Molecular Devices, Sunnyvale, CA). The
assays were conducted in triplicate.
Statistical analysis
All continuous variables were expressed as means ± SD or
means ± SE. ANOVAs, Student t test and Cochran-Mantel-
Haenszel (CMH) test (Row Mean Scores Differ) were used
for statistical comparison among groups.MTSS1 expression
and clinicopathological parameters were analyzed by
Pearson chi-square test or Fisher’s exact test. The survival
analysis was conducted using the Kaplan-Meier method.
The statistical SAS software package (Version 8.2, SAS
Institute, Inc., Cary, NC, USA) was adopted for data ana-
lysis, and the statistical significance was defined as P < 0.05.
Results
MTSS1 located in the central position of the gene
function net of residual HCC
Palliative HCC resection promoted tumor metastasis.
Therefore, we first screened the metastasis-related genes
in HCC tissues to detect the altered genes in residual
tumor. Gene cluster and sample cluster analysis were
based on tumor-related genes found in the HCC tissues
(Fig. 1a). Gene function nets were constructed success-
fully (Fig. 1b, c, d and e). MTSS1 was located in the
central position of the gene function net of residual
HCC (Fig. 1e). Analysis of differential gene expression
showed that the density of the net (Fig. 1f ), which
reflects the relevance of different genes, was higher in
the palliative group (T4 group, 0.0670) than in controls
(T1 group, 0.0145; T2 group, 0.0210; T3 group, 0.0146),
and the condensation degree of the net (Fig. 1g) in re-
sidual HCC (T4 group, 0.1940) was substantially higher
than in the corresponding control group (T1 group,
0.0098). MTSS1 mRNA expression (Fig. 1h) was up-
regulated in residual HCC (T4 group) when compared
with controls (T1, T2, and T3 groups, P = 0.001, 0.034,
and 0.002, respectively).
Elevated MTSS1 mRNA expression is associated with
poor prognosis
We found that MTSS1 was situated in the central pos-
ition of gene function net of residual HCC in the nude
mice model. We tested MTSS1 expression in tumor
tissues from HCC patients. HCC tissues expressed
higher MTSS1 mRNA level than the control liver tissues
(all P = 0.000, Fig. 2a). MTSS1 mRNA level was signifi-
cantly increased in residual HCC tissues (HCC-P II
group) compared with controls (all P = 0.000, Fig. 2a). In
the meantime, MMP2 was also significantly activated (P
= 0.000, Fig. 2b). There was no difference in MTSS1
mRNA level or MMP2 activity between tissues derived
from HCC-P I and HCC-R groups.
The mean MTSS1/GADPH mRNA level of 0.18 was cal-
culated out in the HCC-P I group. Then, we split the
patients following palliative resection by MTSS1 expres-
sion in residual HCC: > 0.18 (MTSS1-high group, n = 20);
and ≤ 0.18 (MTSS1-low group, n = 17). Correlation of
MTSS1 mRNA expression with their clinicopathological
parameters is displayed in Table 1. A higher level of
MTSS1 mRNA was significantly correlated with tumor
number (P = 0.035), presence of HCC satellite (P = 0.019),
incomplete or no encapsulation (P = 0.008), presence of
vascular invasion (P = 0.042) and advanced TNM stage
(P = 0.033). Further, most of the AFP-negative patients
(9 of 11, 81.8 %) showed higher MTSS1 mRNA levels
Huang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:85 Page 5 of 13
(P = 0.036). No significant association between MTSS1
mRNA and age, sex, liver cirrhosis, tumor size, or γ-
glutamyl transferase was found.
Patients with higher MTSS1 mRNA expression re-
vealed earlier residual HCC (P = 0.000, Fig. 2c), a
higher number of lung metastatic nodules (P = 0.039,
Fig. 2d), and lower 1-year survival rate after the first
resection [40.0 % (8/20) vs. 76.5 % (13/17), P = 0.026].
The survival of the MTSS1-high group was signifi-
cantly shorter than that of the MTSS1-low group (P =
0.023, Fig. 2e). In the MTSS1-high group, when sub-
grouping patients according to the mean value of
MTSS1/GADPH mRNA expression (0.33, n = 20), only
1 out of 9 in those with MTSS1/GADPH mRNA higher
than 0.33 survived for more than 1 year, whereas 7 out
of 11 with MTSS1/GADPH mRNA lower than 0.33
survived for more than 1 year (P = 0.028). There was
no significant difference in the 3-year or 5-year sur-
vival rates.
The cumulative survival rates were 56.8 % (21/37)
for 1 year and 21.6 % (8/37) for 3 years. The 5-year
survival in these patients was 10.8 % (4/37), which
was lower than that of all patients with palliative
resection performed in our hospital between the
years 1958 and 2008 (30.0 %, 826/2754, P = 0.010,
unpublished). None of the 37 patients in the current
study survived longer than 10 years. Transcatheter arterial
chemoembolization (TACE) did not significantly affect
Fig. 1 MTSS1 located in the central position of the gene function net of residual HCC. a the cluster heat map of gene cluster (vertical) and sample cluster
(horizontal) were based on tumor-related genes in HCC. The color red and green represents high and low gene expression, respectively; samples with
expression above mean level (red) are clustered. Gene function nets of HCC were constructed successfully. b gene function nets of HCC from palliative
resection group (HCC tissues T1). c gene function nets of HCC from sham operation group (HCC tissues T2). d gene function nets of HCC from blank
control group (HCC tissues T3). e gene function nets shown that MTSS1 was located in the central position of the gene function net of residual HCC (HCC
tissues T4). f the density value of the gene function net. g the condensation degree of the net. h qRT-PCR analysis shown that palliative resection up-
regulated MTSS1 expression, *P= 0.001, 0.034, and 0.002, respectively, when compared with controls (T1, T2, and T3 groups). The bars indicate
the means ± s.d
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MTSS1 mRNA expression and survival between groups or
subgroups.
Altered MTSS1 expression is correlated with metastatic
potential
To identify the relationship between MTSS1 expression
and metastatic potential of HCC, we examined the MTSS1
expression in different cell lines. Significant differences in
MTSS1 mRNA levels were found between the L02 cell line
without metastatic potential, the Hep3B cell line with very
low metastatic potential, and the MHCC97H cell line with
higher metastatic potential (P = 0.000, 0.001, respectively,
Fig. 3a). The metastatic potential of cell lines increased in
parallel with increased levels of MIM-B protein, encoded
by MTSS1 (Fig. 3b).
The siRNA targetingMTSS1 was constructed successfully
with high transfection efficiency, which markedly inhibited
the invasive ability of MHCC97H cells by 28.9 % (Fig. 3c, d
and e). The number of invaded HCC cells in MTSS1
knockdown group (KD group) was less than in the empty
lentivirus group (NC group) and the blank control group
(CON group, all P = 0.000, Fig. 3f). The MIM-B protein
level in KD group was down-regulated when compared
with controls (Fig. 3g). Gelatin zymography assay showed
that MMP2 activity was decreased significantly (0.6-fold,
P = 0.000, Fig. 3h). Further, in vitro studies showed that
MTSS1 overexpression in Hep3B cells promoted cell inva-
sion by 18.2 % (P = 0.021, Additional file 1: Figure. S2A
and B). The effects of MTSS1 downregulation and overex-
pression in HCC cells were validated by several other
HCC cell lines. MTSS1 downregulation inhibited the in-
vasive ability of HCCLM3 and HCCLM6 cells by 25.7 %
(P = 0.002) and 23.1 % (P = 0.001), respectively, while
MTSS1 upregulation increased the invasive ability of
Fig. 2 Elevated MTSS1 mRNA expression is associated with poor prognosis. a the qRT-PCR analysis of MTSS1 expression in different groups, P = 0.000,
when compared with controls. b MMP2 activity in residual HCC (HCC-P II group); †P = 0.000, when compared with controls; no difference in MTSS1
mRNA level or MMP2 activity between HCC-P I and HCC-R groups. c earlier detection of residual HCC in MTSS1-high group than in MTSS1-low group,
*P = 0.000. d higher number of lung metastatic nodules in MTSS1-high group than in MTSS1-low group, *P = 0.039, when compared with controls.
e longer survival in MTSS1-low group compared with MTSS1-high group, P = 0.023
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SMCC7721 and MHCC97L cells by 14.8 % (P = 0.017)
and 12.5 % (P = 0.011), respectively.
SiRNA targeting MTSS1 attenuates pulmonary metastasis
following palliative resection in nude mice bearing
human HCC xenograft
Subsequently, we used in vivo studies to validate the in
vitro effects of siRNA targeting MTSS1. Two weeks
following palliative HCC resection, the lung metastasis
(Fig. 4a) was upgraded when compared with controls
(P = 0.039, Table 2). In Lenti-MTSS1 group, the pul-
monary metastasis was downgraded after MTSS1
knock down (P = 0.041, Table 2). MMP2 activity of the
residual HCC was also significantly inhibited along
with MTSS1 inhibition in the Lenti-MTSS1 group
when compared with controls (P = 0.003, 0.039, re-
spectively, Fig. 4b and c). Further, no animal experi-
enced therapy-related side effects following siRNA
administration.
Discussion
HCC is one of the deadliest types of cancers, with a mor-
tality of almost 100 % [36]. The mortality of HCC remains
high because the disease is typically diagnosed when it is
already at an advanced stage, when most potential curative
therapies such as resection and transplantation are of lim-
ited efficacy. Recent studies reported that different therap-
ies including surgery [5–7], hepatic artery ligation [37],
insufficient radiofrequency ablation [38–40], and sublethal
heat treatment [41] promoted residual tumor progression.
It is especially important to investigate the underlying
mechanism. Our research team has developed a safe and
reliable method of palliative HCC resection in an orthoto-
pic nude mouse model, and reported that palliative resec-
tion enhances metastatic potential of residual HCC in
liver [5]. In the present study, using this method, we inves-
tigated the precise mechanism mediating this metastasis.
Data from our institution (1958–2008, unpublished) re-
vealed that in HCC patients who underwent hepatectomy
the proportion of cases with palliative HCC resection was
34.0 % (2754/8107). The 5-year survival of patients who
underwent palliative HCC resection (30.0 %, n = 2754)
was much lower than in those who underwent curative
resection (52.6 %, n = 5353). It suggested that HCC pallia-
tive resection may promote HCC aggressive metastasis in
residual tumor. Using gene microarray techniques and
bioinformatics tools, we first found that MTSS1 was
upregulated and situated in the central position of gene
function net of residual HCC in nude mouse models. We
tested the MTSS1 expression in HCC tissues from HCC
patients who underwent palliative hepatectomy. We found
that patients with high MTSS1 expression manifested re-
sidual liver tumors early, higher number of metastatic lung
nodules and lower 1-year survival rates, which suggests that
Table 1 Correlation of tumor MTSS1 mRNA expression level
with clinicopathological parameters of HCC patients
Clinicopathological
parameters





(≤0.18, n = 17) (>0.18, n = 20)
Age 37 0.900
≤ 52 y 20 9 11
> 52 y 17 8 9
Sex 37 0.588
Female 8 3 5
Male 29 14 15
Cirrhosis 37 0.855
Yes 30 14 16
No 7 3 4
Tumor number 37 0.035*
Multiple 20 6 14
Single 17 11 6
Satellite 36a 0.019*
Yes 15 3 12
No 21 13 8
Tumor size, cm 37 0.212
≤ 5 7 5 2
> 5 30 12 18
Encapsulation 37 0.008**




Vascular invasion 36a 0.042*
Yes 21 6 15
No 15 11 4
TNM stage 37 0.033*




AFP level, ng/mL 37 0.036*
≤ 20 11 2 9




≤ 54 19 11 8
> 54 18 6 12
Adjuvant TACE 37 0.815
Yes 16 7 9
No 21 10 11
NOTE: HCC hepatocellular carcinoma, TACE transcatheter
arterial chemoembolization
Significant difference: * < 0.05, ** < 0.01
aNumber less than 37 due to missing data
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Fig. 3 MTSS1/MIM-B expression in different cell lines. a, qRT-PCR analysis of MTSS1 mRNA expression; †P= 0.000, 0.001, respectively, when compared with
cell lines of L02 and Hep3B. b, western blot analysis of MIM-B protein level; the bars indicate the means ± s.d. Stable lentiviral transfection of MHCC97H cells
with siRNA targeting MTSS1, ×200, bar, 50 μm. Invasion assay analysis shown that the number of transfected HCC cells (original magnification, × 200)
after treatment with MTSS1 siRNA lentivirus (e) was lower than that of controls (c, d), bar, 50 μm. f, the difference in invasiveness, *P = 0.000, when
compared with controls. The assays were conducted in triplicate. The bars indicate the means ± s.d. g, western blot analysis demonstrated that MIM-B
was down-regulated by siRNA. h, results of gelatin zymography assay shown that MMP2 activity was inhibited (0.6-fold) by siRNA, P = 0.000, compared
with controls
Fig. 4 SiRNA targeting MTSS1 attenuates pulmonary metastasis following palliative resection in nude mice bearing human HCC xenograft.
a, two pulmonary metastatic nodules (arrows, original magnification, × 200), bar, 50 μm. b, MMP2 activity was inhibited by siRNA targeting
MTSS1 in vivo, †P = 0.003 compared with controls. c, qRT-PCR analysis demonstrated that MTSS1 expression was inhibited by siRNA in vivo,
*P = 0.039 compared with controls. The bars indicate the means ± s.d
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HCC patients with high MTSS1 expression have a poor
prognosis and a higher mortality following palliative hepa-
tectomy. No significant changes in the survival rates were
detected between high- and low-MTSS1 groups after 3 or
5 years, which might be an artifact of the small sample size
as few patients survived beyond the first year, especially in
high-MTSS1 high patients. Notably, the MTSS1 levels were
higher in cancers at advanced stage than in early stage, in
our study. In contrast, Ma et al. reported that patients with
early pTNM stage (I-II) manifested high MIM-B mRNA
expression [14]. Consistent with our study, other studies
reported that the positive expression rates of MTSS1 were
significantly higher in advanced stages of colorectal cancer
[20] and cervical carcinoma [21]. Interestingly, most AFP
negative patients (9 of 11, 81.8 %) showed higher MTSS1
mRNA levels in this study, suggesting that MTSS1 may be
another early predictor of residual HCC, which merits in-
vestigation with a large group of patients.
The cumulative 5-years-survival rate in this group of
37 cases (10.8 %, 4/37) was lower than in all patients
undergoing palliative resection at our hospital during
1958 – 2008 (30.0 %, 826/2754). The reasons may be re-
lated partially to reoperation 37 cases. In another group
of 2754 cases, patients underwent reoperation, TACE or
other therapeutic methods, which suggested that pallia-
tive reoperation decreases 5-years-survival rate. There-
fore, we may increase the 5-years-survival rate with
reasonable therapeutic care of patients undergoing pal-
liative resection. However, this hypothesis requires fur-
ther investigation in a larger number of cases.
Our in vitro studies found that the MTSS1/MIM-B
expression was increased in parallel with the metastatic
potential of cell lines. Downregulation of MTSS1 reduced
the invasive potential of HCC cells and prevented the
exacerbated of lung metastasis following palliative resec-
tion in nude mice bearing HCC xenografts. MTSS1/MIM-
B is also found upregulated in the early stages of several
cancers, including melanomas [42], head and neck squa-
mous cell carcinoma [43], and lung cancer [22]. MIM-B
mRNA and protein is also proved overexpressed in HCC
[14]. Therefore, we believe that advanced lung metastasis
after palliative surgery may correlate with upregulated
MTSS1 expression.
In our study, patients had chronic hepatitis B infection
which progressed to HCC, and we found that the poor
prognosis of hepatitis B-related HCC patients following
palliative hepatectomy associates with elevated MTSS1
mRNA expression. Thus, to dissect the regulation of
MTSS1 expression in HCC may provide a new research
field for HCC diagnosis and treatment. Previous study
demonstrated that p63 could control the cell migration
and invasion by regulating the MTSS1 expression in
breast tumor cells [44]. Recent reports revealed that
chronic hepatitis B infection could induce gene expres-
sion in several of cancers [45, 46]. Therefore, there is a
possibility that the virus infection plays some role in the
expression of MTSS1, which needs further study to iden-
tify the role of chronic hepatitis B infection in MTSS1
regulation in HCC. Furthermore, p63 may affect cell
migration and invasion by regulating the MTSS1 expres-
sion in HCC that remains to be fully elucidated.
The mechanism of MTSS1 upregulation in HCC after
palliative surgery is unclear. The altered microenviron-
ment may be a key player. Predina et al. reported the
absence of any changes in the tumor cells per se but ra-
ther in the surrounding tumor microenvironment after
surgery [47]. Surgery generates a sequence of events to
induce wound healing and is characterized by the release
of VEGF, PDGF, prostaglandins, TGF-beta, clotting fac-
tors, and complement [47–49], which may contribute to
the high levels of MTSS1 by as unknown mechanism.
Cancer metastasis involves basement membrane inva-
sion by MMP activation [50]. A higher level of MMP2
has been related to a poorer prognosis in HCC patients
[35, 51–53]. Our results revealed that MTSS1 expres-
sion, MMP2 activity and lung metastasis were increased
after palliative hepatectomy both in nude mice models
and in HCC patients. After down-regulating MTSS1 ex-
pression, the MMP2 activity and lung metastasis were
also decreased. The synchronous alteration of MMP2
with MTSS1 suggests that MTSS1 promotes tumor me-
tastasis by targeting MMP2. Based on our in vitro and in
vivo studies, we believe that the metastasis-enhancing ef-
fect of palliative resection may partially be due to the
dysregulation of the MIM-B/MMP2 pathway. We found
MMP2 was activated after palliative HCC resection [5].
However, the mechanism underlying MTSS1-mediated
MMP2 activation is still unclear. Further, MTSS1 en-
codes an intracellular MIM that is implicated in actin
cytoskeletal reorganization, and MTSS1 represents a
novel signaling pathway from PDGF receptor to the
Table 2 Effects of palliative resection and Lenti-MTSS1 on
pulmonary metastasis




(n) I II III-IV
Palliative Resection 35 12 11 12
Sham Operation 33 19 8 6
Black Control 32 20 7 5
BBS 32 9 10 13
Lenti-GFP 31 8 11 12
Lenti-MTSS1 30 15 10 5
NOTE: All pulmonary metastases were verified via histological examination
when mice were sacrificed 2 weeks following palliative resection, or receiving
BBS, Lenti-GFP, or Lenti-MTSS1. Lung metastatic extent was graded by number
of tumor cells counted in the maximum section of the solitary pulmonary
metastatic nodule. *P = 0.039 or 0.041 when Palliative Resection group or
Lenti-MTSS1 group was compared among Control groups, respectively
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actin cytoskeleton via Src-related kinases [54]. Therefore,
MTSS1 depletion affects the cytoskeletal reorganization.
Giacobbe et al. reported that MTSS1 enhances breast
tumor cell migration resulting in poor prognosis [44]. We
concluded that MTSS1 depletion affects the migratory
capabilities of HCC cells, which needs further investigation.
Currently, there are several limitations in - and resist-
ance to the therapy of HCC, thus, there is a necessary
need for development of new and more effective thera-
peutic alternatives [55, 56]. In this study, patients with
increased MTSS1 expression in residual HCC showed
the worst prognosis. Downregulation of MTSS1 success-
fully averted pulmonary metastasis in our mouse model.
The findings suggest that individualized treatment tar-
geting high MTSS1 expression may be an effective strat-
egy to treat HCC.
There are some limitations in this study. The nature of
the nude mice lowers the strength of evidence. The size
of our patient population is relatively small, which may
lead to selection bias. Finally, we cannot exclude the
possibility that other downstream pathways of MTSS1
might also mediate HCC metastasis after palliative hep-
atectomy. Therefore, the precise mechanism triggering
metastasis remains to be fully elucidated. Despite
these limitations, we believe that the current study
provides preliminary and powerful data underscoring
the value of MTSS1/MIM-B expression in HCC diag-
nosis and treatment.
Conclusions
In summary, palliative HCC resection upregulates MTSS1
mRNA expression, activates MMP2 activation and en-
hances residual HCC metastasis to lung. Patients with
hepatitis B-related HCC exhibiting high MTSS1 mRNA
levels in the residual tumor show poor prognosis after
hepatectomy. However, additional investigations into the
mechanisms underlying the role of MTSS1/MIM-B in me-
tastasis are needed, to facilitate the search for novel thera-
peutic strategies for HCC, and improve prognosis of
patients with HCC undergoing hepatectomy.
Abbreviations
AFP, α-fetoprotein; BBS, borate-buffered saline; ELISA, enzyme-linked
immunosorbent assay; GEO, Gene expression omnibus; H&E, Hematoxylin
and eosin; HCC, hepatocellular carcinoma; MIM, missing in metastasis; MMP2,
matrix metalloproteinase 2; MTSS1, metastasis suppressor 1; PCR, polymerase
chain reaction; PDGF, platelet derived growth factor; SDS-PAGE, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis; siRNA, small interfering
RNA; SVM, Support vector machine; TACE, Transcatheter arterial chemoembolization;
TGF-beta, transforming growth factor beta; VEGF, vascular endothelial
growth factor.
Additional file
Additional file 1: Figure S1. The invasive ability (% of control) of
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